Abstract:Abstract Background Covid-19 became a global pandemic in 2019. Studies have shown that coronavirus can cause neurological symptoms, but clinical studies on its neurological symptoms are limited. In this meta-analysis, we aimed to summarize the various neurological manifestations that occurred in COVID-19 patients and calculate the incidence of various neurological manifestations. At the same time, we further explored the mechanism of nervous system injury and prognosis in COVID-19 patients in combination with their nervous system manifestations. This study provides a reference for early clinical identification of COVID-19 nervous system injury in the future, so as to achieve early treatment and reduce neurological sequelae. Methods We systematically searched all published English literature related to the neurological manifestations of COVID-19 from January 1, 2020, to April 30, 2021, in Pubmed, Embase, and Cochrane Library. The keywords used were COVID-19 and terminology related to the nervous system performance. All included studies were selected by two independent reviewers using EndNote and NoteExpress software, any disagreement was resolved by consensus or by a third reviewer, and the selected data were then collected for meta-analysis using a random-effects model. Results A total of 168 articles (n = 292,693) were included in the study, and the meta-analysis showed that the most common neurological manifestations of COVID-19 were myalgia(33%; 95%CI 0.30–0.37; I 2 = 99.17%), smell impairment(33%; 95%CI 0.28–0.38; I 2 = 99.40%), taste dysfunction(33%; 95%CI 0.27–0.39; I 2 = 99.09%), altered mental status(32%; 95%CI 0.22–0.43; I 2 = 99.06%), headache(29%; 95%CI 0.25–0.33; I 2 = 99.42%), encephalopathy(26%; 95%CI 0.16–0.38; I 2 = 99.31%), alteration of consciousness(13%; 95%CI 0.08–0.19; I 2 = 98.10%), stroke(12%; 95%CI 0.08–0.16; I 2 = 98.95%), dizziness(10%; 95%CI 0.08–0.13; I 2 = 96.45%), vision impairment(6%; 95%CI 0.03–0.09; I 2 = 86.82%), intracerebral haemorrhage(5%; 95%CI 0.03–0.09; I 2 = 95.60%), seizure(4%; 95%CI 0.02 -0.05; I 2 = 98.15%), encephalitis(2%; 95%CI 0.01–0.03; I 2 = 90.36%), Guillan-Barré Syndrome (GBS) (1%; 95%CI 0.00–0.03; I 2 = 89.48%). Conclusions Neurological symptoms are common and varied in Covid-19 infections, and a growing number of reports suggest that the prevalence of neurological symptoms may be increasing. In the future, the role of COVID-19 neurological symptoms in the progression of COVID-19 should be further studied, and its pathogenesis and assessment methods should be explored, to detect and treat early neurological complications of COVID-19 and reduce mortality.

Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis

Neurological and Psychiatric Presentations Associated with COVID-19

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review

Current Clinical Findings of Acute Neurological Syndromes after SARS‐CoV‐2 Infection

Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

The neurobiology of SARS-CoV-2 infection

The Neurological Implications of COVID-19: A Comprehensive Narrative Review

Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications

What can the neurological manifestations of COVID-19 tell us: a meta-analysis

Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions

Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions

Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients

Targeted metabolomics identifies accurate CSF metabolite biomarkers for the differentiation between COVID-19 with neurological involvement and CNS infections with neurotropic viral pathogens

The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation

Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19

COVID-19 and central nervous system interplay: A big picture beyond clinical manifestation

Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid

Neurological Complications of COVID-19: A Systematic Review of Literature

Neurologic aspects of covid-19: a concise review

Central and peripheral kynurenine pathway metabolites in COVID-19: Implications for neurological and immunological responses

Possible mechanism of central nervous system targeting and neurological symptoms of the new-coronavirus (COVID-19): literature review